These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
285 related items for PubMed ID: 23689085
1. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Flechner SM, Gurkan A, Hartmann A, Legendre CM, Russ GR, Campistol JM, Schena FP, Hahn CM, Li H, Korth-Bradley JM, Tai SS, Schulman SL. Transplantation; 2013 May 27; 95(10):1233-41. PubMed ID: 23689085 [Abstract] [Full Text] [Related]
2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group. Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398 [Abstract] [Full Text] [Related]
3. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group. Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978 [Abstract] [Full Text] [Related]
4. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT. Transplant Proc; 2005 Mar 27; 37(2):693-6. PubMed ID: 15848504 [Abstract] [Full Text] [Related]
5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508 [Abstract] [Full Text] [Related]
6. New approaches to de novo immunosuppression and steroid elimination. Lebranchu Y. Transplant Proc; 2009 Nov 27; 41(6 Suppl):S39-41. PubMed ID: 19651295 [Abstract] [Full Text] [Related]
7. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus. Tedesco-Silva H, Garcia VD, Contieri FL, De Boni Monteiro de Carvalho D, Noronha IL, Gonçalves RT, de Paula FJ, Abbud-Filho M, Manfro RC, David-Neto E, Alfieri F, Ikehara E, Jiang Q, Tai SS, Medina-Pestana JO. Transplant Proc; 2010 Jun 27; 42(5):1659-66. PubMed ID: 20620495 [Abstract] [Full Text] [Related]
8. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group. Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789 [Abstract] [Full Text] [Related]
9. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM, Kobashigawa J, Klintmalm G. Clin Transplant; 2008 Dec 15; 22(1):1-15. PubMed ID: 18217899 [Abstract] [Full Text] [Related]
10. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. Mühlbacher F, Neumayer HH, del Castillo D, Stefoni S, Zygmunt AJ, Budde K, European Rapamune Cyclosporine Minimization Study Group. Transpl Int; 2014 Feb 15; 27(2):176-86. PubMed ID: 24266855 [Abstract] [Full Text] [Related]
11. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ. Transplantation; 2007 Apr 15; 83(7):883-92. PubMed ID: 17460558 [Abstract] [Full Text] [Related]
12. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Baboolal K. Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239 [Abstract] [Full Text] [Related]
13. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment. Pliszczynski J, Kahan BD. Transplant Proc; 2011 Dec 27; 43(10):3657-68. PubMed ID: 22172822 [Abstract] [Full Text] [Related]
14. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group. Transpl Int; 2005 Jan 27; 18(1):22-8. PubMed ID: 15612979 [Abstract] [Full Text] [Related]
15. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J. Transplant Proc; 2009 Dec 27; 41(10):4138-46. PubMed ID: 20005355 [Abstract] [Full Text] [Related]
16. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P. Transplantation; 2000 Apr 15; 69(7):1252-60. PubMed ID: 10798738 [Abstract] [Full Text] [Related]
17. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA. Transplant Proc; 2012 Jan 15; 44(1):154-60. PubMed ID: 22310603 [Abstract] [Full Text] [Related]
18. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation]. Zhu L, Ding T, Wang XX, Lin ZB, Chen G. Zhonghua Yi Xue Za Zhi; 2016 May 31; 96(20):1556-61. PubMed ID: 27266681 [Abstract] [Full Text] [Related]
19. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS. Transplantation; 2015 Jan 31; 99(1):180-6. PubMed ID: 24983307 [Abstract] [Full Text] [Related]
20. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M. Am J Kidney Dis; 2010 Feb 31; 55(2):335-43. PubMed ID: 19926370 [Abstract] [Full Text] [Related] Page: [Next] [New Search]